期刊文献+

结直肠癌与不同上皮内瘤变腺瘤中PI3Kp110β的表达及临床意义 被引量:6

Expression and clinical significance of PI3Kp110β in human colorectal carcinoma and colorectal adenoma with different grades of dysplasia
下载PDF
导出
摘要 目的探讨PI3Kp110β表达与结直肠癌发生、发展的相关性及其临床意义。方法应用免疫组化EnVision法检测PI3Kp110β在138例结直肠腺癌、29例低级别上皮内瘤变(low-grade intraepithelial neoplasia,LGIN)腺瘤、35例高级别上皮内瘤变(high-grade intraepithelial neoplasia,HGIN)腺瘤、10例结肠正常黏膜组织中的表达情况。结果 (1)PI3Kp110β在结直肠癌组织中的表达明显高于结直肠LGIN腺瘤、HGIN腺瘤及正常黏膜组织,其差异有统计学意义(P<0.05),PI3Kp110β在结直肠HGIN腺瘤组织中的表达与结直肠LGIN腺瘤、正常黏膜组织中的表达相比,差异无显著性(P>0.05);(2)结直肠癌组织中PI3Kp110β的表达与肿瘤的发生部位、分化程度、临床分期及淋巴结转移等临床因素间具有相关性(P<0.05),与患者的性别、年龄及肿瘤大小等因素无关(P>0.05)。结论 PI3Kp110β异常表达可能在结直肠癌的发生、发展中发挥着重要作用,检测PI3Kp110β对评判结直肠癌的生物学行为及预后有一定临床意义。 Purpose To investigate PI3Kp110β expression in the occurrence and the development of human colorectal carcinoma and discuss its clinical significance. Methods The expression of PI3Kp110β was detected in 138 cases of adenocarcinoma, 29 cases of low-grade intraepithelial neoplasia, 35 cases of high-grade intraepithelial neoplasia, and 10 cases of normal mueosa by EnVision immu- nohistochemical method. Results (1)The expression of PI3Kp11013 in adenocarcinoma was higher than those in adenoma with low- grade intraepithelial neoplasia, adenoma with high-grade intraepithelial neoplasia, normal mucosa which was significantly difference (P 〈 0. 05 ). ( 2 ) The expression of PI3 Kp110β was closely correlated with the location, differentiation, metastasis and TNM staging ( P 〈 0.05 ), hut unrelated to gender, age and size of the tumour( P 〉 0.05 ). Conclusions PI3Kp110β may play an important role in the development or progression of colorectal carcinoma.
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2012年第5期518-521,共4页 Chinese Journal of Clinical and Experimental Pathology
关键词 结直肠肿瘤 上皮内瘤变 腺瘤 PI3Kp110β 临床意义 colorectal neoplasms intraepithelial neoplasia adenoma PI3Kp110β clinic significance
  • 相关文献

参考文献14

  • 1Katso R,Okkenhaug K,Ahnladi K,et al.Cellular function of phosphoinositide 3-kinases:implications for development,homeostasis,and cancer[J].Annu Rev Cell Dev Biol,2001,17:615-75.
  • 2李扬扬,吴淑华,刘鲁英,朱玉红.大肠癌组织PIK3CA蛋白表达及其与大肠癌耐药相关性的研究[J].中华肿瘤防治杂志,2010,17(12):933-936. 被引量:6
  • 3周晓军,樊祥山.解读2010年消化系统肿瘤WHO分类(Ⅰ)[J].临床与实验病理学杂志,2011,27(4):341-346. 被引量:96
  • 4Bosman F T,Carneiro F,Hruban R H,et al.World Health Organization classification of tum ours of the digestive system[M].Lyon:IARC Press,2010:1-155.
  • 5Kerr D.Clinical development of gene therapyfor colorectal cancer[J].Nat Rev Cancer,2003,3(8):615-22.
  • 6胡其泰,胡凤英,田旭阳,杨莉,陈言东,党彤.结直肠不同异型增生腺瘤与癌的关系[J].临床与实验病理学杂志,2011,27(7):702-706. 被引量:11
  • 7Marqués M,Kumar A,Poveda A M,et al.Specific function of phosphoinositide 3-Kinase beta in the control of DNA replication[J].Proc Natl Acad Sci U S A,2009,106(18):7525-30.
  • 8Ciraolo E,Iezzi M,Marone R,et al.Phosphoinositide 3-kinase p110beta activity:key role in metabolism and mammary gland cancer but not development[J].Sci Signal,2008,1(36):1-11.
  • 9Benistant C,Chapuis H,Roche S.A specific function for phosphatidylinositol 3-kin-ase alpha (p85alpha-pl10alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells[J].Oncogene,2000,19(44):5083-90.
  • 10Chen H,Mei L,Zhou L,et al.PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts[J].J Neurooncol,2011,104(1):155-67.

二级参考文献66

  • 1郑杰.结直肠息肉和结直肠癌[J].中华病理学杂志,2005,34(1):4-5. 被引量:65
  • 2来茂德.结直肠腺瘤诊断名称的应用[J].临床与实验病理学杂志,2006,22(2):129-131. 被引量:6
  • 3夏曙,于世英.PI3K/Akt信号转导通路在恶性肿瘤中的研究进展[J].肿瘤,2006,26(6):576-578. 被引量:28
  • 4张燕,金先庆,赵珍珍,宿玉玺.5种耐药基因在成人常见恶性肿瘤中的表达特点[J].重庆医科大学学报,2007,32(10):1023-1026. 被引量:16
  • 5Starrovskaya A A. Cellular mechanisms of multidrug resistance of tumor cells[J]. Biochemistry (Mosc), 2000, 65(1) :95-106.
  • 6虞积耀.世界卫生组织肿瘤分类及诊断标准系列-消化系统肿瘤病理学和遗传学[M].北京:人民卫生出版社,2006:132-135.
  • 7Volinia S, Hiles I, Ormondoryd E, et al. Molecularcloning, cDNA sequence,and Chromosomal locolization of the human phosphatidylinositol 3- kinase p110 alpha (PIK3CA) gene[J]. Genomies, 1994,24(3) 472-477.
  • 8Vivanco I,Sawyers C L. The phosphatidylinositol 3-kinase AKT pathway in human cancer[J]. Nat Rev Cancer, 2002, 2(7): 489-501.
  • 9Cantley L C. The phosphoinositide 3-kinase pathway[J], Science (Wash DC), 2002,296(5573) :1655-1657.
  • 10Broderick D K, Di C, Parrett T J, et al. Mutation of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas and medulloblastomas[J]. Cancer Res, 2004, 64 (15) : 5048-5050.

共引文献135

同被引文献81

  • 1Gyrgyi Müzes,Zsolt Tulassay,Ferenc Sipos.Interplay of autophagy and innate immunity in Crohn's disease: A key immunobiologic feature[J].World Journal of Gastroenterology,2013,19(28):4447-4454. 被引量:6
  • 2Laurent-Puiq P,Aqostini J,Maley K. Colorectaloncogenesis[J].Bulletin Du Cancer,2010,(11):1311-1321.
  • 3Izycka-Swieszewska E,Brzeskwiniewicz M,Wozniak A. EGFR,PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours[J].Folia Neuro Pathol,2010,(04):238-245.
  • 4Dbouk H A,Backer J M. A beta version of life:p110β takes center stage[J].Oncotarget,2010,(08):729-733.
  • 5Carnero A,Blanco-Aparicio C,Renner O. The PTEN/PI3K/AKT signalling pathway in cancer,therapeutic implications[J].Current Cancer Drug Targets,2008,(03):187-198.doi:10.2174/156800908784293659.
  • 6Yuan T L,Cantley L C. PI3K pathway alterations in cancer:variations on a theme[J].Oncogene,2008,(41):5497-5510.doi:10.1038/onc.2008.245.
  • 7Xing M. Recent advances in molecular biology of thyroid cancer and their clinical implications[J].Otolaryngologic Clinics of North America,2008,(06):1135-1146.
  • 8Zhao L,Vogt P K. Helical domain and kinase domain mutations in p110 of Phosphate-dylinositol 3-kinase induce gain of function by differert mechanisms[J].Proceedings of the National Academy of Sciences(USA),2008,(07):2652-2657.
  • 9Hutti J E,Pfefferle A D,Russell S C. Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation[J].Cancer Research,2012,(13):3260-3269.
  • 10Janku F,Wheler J J,Westin S N. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations[J].Journal of Clinical Oncology,2012,(08):777-782.

引证文献6

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部